Seres Therapeutics Announces Appointment of Richard N. Kender as Executive Chair and Interim CEO; Provides Business Updates

Core Insights - Seres Therapeutics is advancing its corporate strategy focused on live biotherapeutic programs targeting inflammatory and immune diseases, particularly inflammatory bowel disease and immune checkpoint-related enterocolitis, with clinical data from the SER-155 study expected in Q2 2026 [1][3][5] Leadership Changes - Richard N. Kender has been appointed as Executive Chair and Interim CEO, bringing over 35 years of biopharma experience, while previous co-CEOs will continue in their roles as Chief Legal Officer and Chief Financial Officer [2][4][5] Clinical Development - SER-155 is ready for Phase 2 trials for patients undergoing allogeneic hematopoietic stem cell transplant to treat hematologic malignancies, with ongoing efforts to secure funding for the program [1][5][11] - The SER-155 study is fully enrolled with 15 participants, and initial clinical data is anticipated in Q2 2026, focusing on safety, efficacy, and pharmacology [11][13] Financial Position - As of December 31, 2025, Seres had approximately $45.8 million in cash and cash equivalents, with expectations to fund operations through Q3 2026 [8][10] Pipeline Updates - The company is also advancing SER-603, a novel live biotherapeutic candidate aimed at treating inflammatory bowel disease, with IND-enabling activities underway [11][13]